// Real-Time Intelligence Feed

Financial Intelligence.
Real-Time.

SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.

22,978
Stories Indexed
Live
Feed Status
6
Data Sources
LATEST
AllEarningsFDAM&AInsider TradingRegulatoryOfferingLeadershipRestructuringDividendInstitutional HoldingsBankruptcy
ALL STORIES · 22,978 results Live
Restructuring GTBP Sep 3 ▲ +0.50

Gt Biopharma Eliminates Series A Preferred Stock

GT Biopharma’s board approved a resolution to eliminate its Series A Preferred Stock from its Restated Certificate of Incorporation via a filing with Delaware authorities. This mov…

Other RRBI Sep 3 — 0.00

Red River Bancshares investor presentation filed with SEC.

Red River Bancshares Inc. filed an exhibit, EX-99.1, which is an investor presentation as of June 30, 2026. The document includes forward-looking statements and risk factors typica…

Institutional Holdings 13F-HR/A Sep 3 — 0.00

13F-HR/A - ANCHOR CAPITAL ADVISORS LLC (0000813933) (Filer)

Institutional holdings report (13F-HR) for the period ended 2026-06-30 filed by 13F-HR/A - ANCHOR CAPITAL ADVISORS LLC (0000813933) (Filer).

Earnings ODFL Sep 3 — 0.00

ODFL Reports August LTL Operating Metrics

ODFL reported increased LTL revenue per hundredweight and day, driven by service strength. Nonetheless, the company warned of numerous risks that could materially affect future res…

Offering FHLBP Sep 3 — 0.00

FHLB Pittsburgh Issues $64M in Bonds

The Bank issued $66.5M in aggregate principal amount of debt due between 2028 and 2046. The issuance is not material to the Bank's financial results or market position.

M&A PLTNU Sep 3 — +0.10

Plutonian II to merge with mineral explorer NT1 Resources

Plutonian Acquisition Corp. II signed a definitive agreement to merge with Australian mineral exploration company NT1 Resources, valuing the deal at approximately $500 million. The…

Regulatory SMMT Sep 3 — +0.10

Ivonescimab Monotherapy Demonstrates Significant OS Benefit vs. Pembrolizumab in Phase III HARMONi-2 Study

Summit partner Akeso announced positive overall survival results from the Phase III HARMONi-2 trial in NSCLC. Ivonescimab, licensed for Summit's territories as SMT112, showed stati…

Guidance|Restructuring TSN Sep 3 ▼ -0.40

Tyson Updates Fiscal 2026 Outlook Amid Beef Segment Pressures

Tyson Foods lowered its Beef segment guidance due to severe cattle shortages and margin compression, reducing its expected revenue growth and adjusted operating income for fiscal 2…

Earnings WLY Sep 3 — 0.00

Wiley reports Q1 results, reaffirms outlook

Wiley reported First Quarter 2027 revenue of $386 million and reaffirmed its full-year guidance, with strength in Research and AI offsets by softness in Learning and prior-year com…

Regulatory FFIE Sep 3 — 0.00

FF AI-Robotics ratifies amended consulting agreement with AIBOT, Inc.

FARADAY FUTURE AI-Robotics AIBOT INC. PDF 99-1 AMENDED SERVICES SCOPE ADDS TIMELINES U.S. COMPLIANCE DELIVERABLES

Leadership WAM Sep 3 ▲ +0.50

Alaska Silver issues 375,000 stock options to non-executive directors

Alaska Silver Corp. announced the issuance of 375,000 stock options to non-executive directors with a five-year term. This leadership compensation move aligns with the company's co…

Regulatory APVO Sep 3 ▲ +1.00

Aptevo reports 93% clinical benefit rate with mipletamig triplet in TP53-mutated AML

Aptevo Therapeutics reported a 93% clinical benefit rate in evaluable TP53-mutated AML patients treated with its mipletamig triplet, nearly double published venetoclax outcomes, sh…

Regulatory CXAI Sep 3 ▲ +0.70

Nasdaq Finds CXApp Regained Compliance

On September 2, 2026, CXApp confirmed it regained compliance with Nasdaq listing requirements after the company's stock closed at or above $1.00 for the last 10 consecutive busines…

Regulatory CLYM Sep 3 ▲ +0.80

Climb Bio's CLYM116 Shows Durable APRIL Suppression in Phase 1 Trial

Climb Bio reported Phase 1 data for anti-APRIL antibody CLYM116 demonstrating a ~29-day half-life and >90% APRIL suppression, supporting every-12-week dosing. The company expects i…

M&A EQBK · LBCN Sep 3 — 0.00

Equity Bancshares to acquire Lincoln Bancorp

Equity Bancshares Inc. plans to acquire Lincoln Bancorp in a $1.34 billion deal to expand its network. This merger, signed on Sept. 2, 2026, will combine the two community bank bra…

Offering HLMN Sep 3 — 0.00

Hillman amends credit agreement for $200M incremental term loan facility

Hillman Solutions Corp. entered into an amendment to its credit agreement to secure a $200 million incremental term loan facility primarily for acquiring Kanebridge, LLC. The move …

Earnings SAIA Sep 3 — +0.05

Saia reports July and August LTL data

Saia's LTL shipments and tonnage rose for both July and August 2026 versus the same period in 2025, indicating strong freight demand.

M&A CROWN Sep 3 ▲ +0.50

Crown PropTech Acquisitions Amends SPAC Merger Agreement for Rare Earths Acquisition

Crown PropTech entered into an amended and restated business combination agreement to acquire Mkango Rare Earths Limited as of September 2, 2026. The definitive agreement outlines …

Earnings DLTH Sep 3 ▲ +0.50

DLTH Q2 2026 Net Income Improves On Gross Margin Expansion

Duluth Holdings reported net income of $18.4 million versus $1.3 million a year prior, driven by a massive 1,810 basis point gross margin expansion and tariff refunds, alongside a …

Earnings|Guidance CPB Sep 3 — 0.00

Campbell's Q4 2026 Sales Declined, Issues FY27 Guidance

Campbell's Q4 2026 net sales fell 8% driven by softness, while it projects $500M in cost savings by FY 2030 and resets its dividend to accelerate debt reduction.